JP2014531584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531584A5 JP2014531584A5 JP2014530245A JP2014530245A JP2014531584A5 JP 2014531584 A5 JP2014531584 A5 JP 2014531584A5 JP 2014530245 A JP2014530245 A JP 2014530245A JP 2014530245 A JP2014530245 A JP 2014530245A JP 2014531584 A5 JP2014531584 A5 JP 2014531584A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- ccr9
- foxp3
- amount
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 72
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims description 40
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims description 40
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 34
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 24
- 102100033461 Interleukin-17A Human genes 0.000 claims description 24
- 102100037850 Interferon gamma Human genes 0.000 claims description 23
- 108010074328 Interferon-gamma Proteins 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 21
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000003364 immunohistochemistry Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 230000004043 responsiveness Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 239000002771 cell marker Substances 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 101700026522 SMAD7 Proteins 0.000 claims 1
- 102000049873 Smad7 Human genes 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11425234 | 2011-09-15 | ||
| EP11425234.9 | 2011-09-15 | ||
| US201161576556P | 2011-12-16 | 2011-12-16 | |
| US61/576,556 | 2011-12-16 | ||
| PCT/EP2012/068146 WO2013037970A1 (en) | 2011-09-15 | 2012-09-14 | Methods for monitoring responsiveness to anti-smad7 therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014531584A JP2014531584A (ja) | 2014-11-27 |
| JP2014531584A5 true JP2014531584A5 (enExample) | 2015-11-05 |
| JP6389122B2 JP6389122B2 (ja) | 2018-09-12 |
Family
ID=47882658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530245A Expired - Fee Related JP6389122B2 (ja) | 2011-09-15 | 2012-09-14 | 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9791442B2 (enExample) |
| EP (2) | EP3165929A3 (enExample) |
| JP (1) | JP6389122B2 (enExample) |
| KR (1) | KR102099990B1 (enExample) |
| CN (1) | CN104040349B (enExample) |
| AU (1) | AU2012307336B2 (enExample) |
| CA (1) | CA2848595A1 (enExample) |
| ES (1) | ES2617200T3 (enExample) |
| MX (1) | MX350087B (enExample) |
| RU (1) | RU2678450C2 (enExample) |
| WO (1) | WO2013037970A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| ES3034412T3 (en) | 2008-11-13 | 2025-08-18 | Nogra Pharma Ltd | Antisense compositions and methods of making and using same |
| US10081809B2 (en) | 2012-04-18 | 2018-09-25 | University Of Miami | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| JP6502863B2 (ja) * | 2013-03-15 | 2019-04-17 | ノグラ ファーマ リミテッド | 結腸直腸癌を処置する方法 |
| US20160139123A1 (en) * | 2013-07-12 | 2016-05-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Shear Wave Imaging Method and Installation for Collecting Information on a Soft Solid |
| JP2017515896A (ja) * | 2014-05-09 | 2017-06-15 | ノグラ ファーマ リミテッド | 炎症性腸疾患の処置の方法 |
| US10337004B2 (en) * | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| US20170233736A1 (en) * | 2014-10-17 | 2017-08-17 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| MA41271A (fr) * | 2014-12-26 | 2017-10-31 | Celgene Alpine Invest Company Ii Llc | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 |
| EP3329276A2 (en) * | 2015-07-27 | 2018-06-06 | H. Hoffnabb-La Roche Ag | Methods for diagnosing and treating inflammatory bowel disease |
| CA3000569A1 (en) * | 2015-09-30 | 2017-04-06 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
| JP2018529726A (ja) * | 2015-09-30 | 2018-10-11 | セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー | Ｔｌｒ調節因子及び使用方法 |
| WO2017147276A1 (en) | 2016-02-23 | 2017-08-31 | Celgene Corporation | Methods of treating intestinal fibrosis using smad7 inhibition |
| US10517889B2 (en) | 2017-09-08 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Modulators of SMAD7 expression |
| US11619832B2 (en) | 2018-03-08 | 2023-04-04 | Coopervision International Limited | Identification of contact lens wearers predisposed to contact lens discomfort |
| CN110082538B (zh) * | 2019-04-19 | 2021-12-03 | 中山大学附属第六医院 | CCR9+IL-17+Treg细胞在制备用于检测NEC的试剂盒中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
| RU2185627C2 (ru) * | 2000-09-11 | 2002-07-20 | Новосибирская государственная медицинская академия | Способ определения чувствительности (восприимчивости) к внутривенной лазеротерапии больных ишемической болезнью сердца |
| EP1456380B1 (en) | 2001-11-02 | 2012-04-18 | Giuliani International Limited | Smad7 inhibitors for the treatment of cns diseases |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| US20090275496A1 (en) * | 2004-05-07 | 2009-11-05 | Peptimmune, Inc. | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
| ES2563955T3 (es) * | 2005-08-02 | 2016-03-16 | Centenary Institute Of Cancer Medicine & Cell Biology | Método para identificar linfocitos T reguladores |
| CA2643167A1 (en) * | 2006-03-10 | 2007-09-20 | Mount Sinai Hospital | Diagnostic compositions and treatment methods for conditions involving trophoblast cell death, differentiation, invasion and/or cell fusion and turnover |
| WO2008157394A2 (en) * | 2007-06-13 | 2008-12-24 | La Jolla Institute For Allergy And Immunology | Regulatory t cells and methods of making and using same |
| US20110008795A1 (en) | 2008-02-28 | 2011-01-13 | Sysmex Corporation | Marker for detection of il-17-producing helper t-cell, and method for detection of il-17-producing helper t-cell |
| JP2010051307A (ja) * | 2008-07-28 | 2010-03-11 | Eisai R & D Management Co Ltd | Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法 |
| ES3034412T3 (en) | 2008-11-13 | 2025-08-18 | Nogra Pharma Ltd | Antisense compositions and methods of making and using same |
| ES2558729T3 (es) | 2009-07-10 | 2016-02-08 | Transgene Sa | Biomarcador para la selección de pacientes y procedimientos relacionados |
| US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| US10081809B2 (en) | 2012-04-18 | 2018-09-25 | University Of Miami | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| JP6502863B2 (ja) | 2013-03-15 | 2019-04-17 | ノグラ ファーマ リミテッド | 結腸直腸癌を処置する方法 |
| JP2017515896A (ja) | 2014-05-09 | 2017-06-15 | ノグラ ファーマ リミテッド | 炎症性腸疾患の処置の方法 |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| US20170233736A1 (en) | 2014-10-17 | 2017-08-17 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| CA3000569A1 (en) | 2015-09-30 | 2017-04-06 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
-
2012
- 2012-09-14 AU AU2012307336A patent/AU2012307336B2/en not_active Ceased
- 2012-09-14 CN CN201280056296.8A patent/CN104040349B/zh not_active Expired - Fee Related
- 2012-09-14 ES ES12759150.1T patent/ES2617200T3/es active Active
- 2012-09-14 EP EP16184629.0A patent/EP3165929A3/en not_active Ceased
- 2012-09-14 KR KR1020147009572A patent/KR102099990B1/ko not_active Expired - Fee Related
- 2012-09-14 RU RU2014114838A patent/RU2678450C2/ru not_active IP Right Cessation
- 2012-09-14 WO PCT/EP2012/068146 patent/WO2013037970A1/en not_active Ceased
- 2012-09-14 MX MX2014003295A patent/MX350087B/es active IP Right Grant
- 2012-09-14 US US14/344,969 patent/US9791442B2/en not_active Expired - Fee Related
- 2012-09-14 CA CA2848595A patent/CA2848595A1/en not_active Abandoned
- 2012-09-14 EP EP12759150.1A patent/EP2748611B1/en not_active Not-in-force
- 2012-09-14 JP JP2014530245A patent/JP6389122B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-15 US US15/705,715 patent/US20180128829A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014531584A5 (enExample) | ||
| RU2014114838A (ru) | Способы контроля восприимчивости анти-smad7 терапии | |
| JP6941324B2 (ja) | 新規な肝硬変または肝線維症のマーカー | |
| Singh et al. | First mass screening of the human population to estimate the bio-load of Mycobacterium avium sub-species paratuberculosis in North India | |
| JP2023126213A (ja) | 細胞媒介免疫応答アッセイ | |
| Singh et al. | Inflammatory chemokines and their receptors in human visceral leishmaniasis: Gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells | |
| Veroni et al. | Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis | |
| Golby et al. | MicroRNA expression profiling of PPD-B stimulated PBMC from M. bovis-challenged unvaccinated and BCG vaccinated cattle | |
| CN112608995B (zh) | 一种肺结核病特异性标志物及应用和试剂盒 | |
| Mallikarjunappa et al. | Functional analysis of bovine interleukin-10 receptor alpha in response to Mycobacterium avium subsp. paratuberculosis lysate using CRISPR/Cas9 | |
| Hewitt et al. | A prime-boost concept using a T-cell epitope-driven DNA vaccine followed by a whole virus vaccine effectively protected pigs in the pandemic H1N1 pig challenge model | |
| CN108845129A (zh) | 一种活动性结核类疾病的生物标志物的应用 | |
| KR101476781B1 (ko) | 결핵 진단용 바이오마커 마이크로 rna | |
| Stepanova et al. | Different immune response of pigs to Mycobacterium avium subsp. avium and Mycobacterium avium subsp. hominissuis infection | |
| CN107267659B (zh) | 检测trim基因和/或蛋白水平的产品的用途 | |
| CN118979104A (zh) | 脓毒症相关疾病早期诊断标志物及其用途 | |
| CN106520916B (zh) | lncRNA-MIR3945HG V2在菌阴肺结核诊断中的应用 | |
| CN103882134A (zh) | 一种用于检测阴道加德纳菌的引物对、试剂盒及其应用 | |
| Loy et al. | Plasma Cell-Free RNA Captures Immune Dynamics and Predicts GVHD after Hematopoietic Stem Cell Transplantation | |
| WO2016176789A1 (es) | Biomarcadores para predecir respuesta a un tratamiento inmunomodulador en pacientes con enfermedad inflamatoria | |
| Jiménez et al. | Expression of non-replicating persistence associated genes of Mycobacterium bovis in lymph nodes from skin test-reactor cattle | |
| CN113755614A (zh) | 布鲁氏菌病疫苗株与野毒株快速高灵敏鉴别诊断试剂盒及其使用方法 | |
| WO2022051816A1 (en) | Methods of determining immune response | |
| RU2781235C1 (ru) | Способ определения наличия реакции Т-клеток в крови человека на присутствие антигенов SARS-CoV2 | |
| CN107557367B (zh) | Ighg1基因突变体及其应用 |